The Veet hair removal system for hairy gorillas is flying off the shelf.

This surely has to be a buy? DYOR

http://www.reckittbenckiser.com/

RB trying £36 again (3 month high just gone)

New high 3858 hit earlier.

3rd Quarter results

Highlights:

* Year to date like-for-like (LFL) net revenue growth (ex RBP) of +4%, driven
by strong Emerging Markets Areas (EM) growth.

* Strong Q3 LFL growth +5% (+5% ex RBP).

* Europe North America (ENA) Q3 LFL growth +2%. This improved performance was
driven by higher brand equity investment (BEI), a good start for the new
Mucinex Fast Max and a stabilising promotional environment in laundry care
and Vanish.

* YTD global growth driven by Dettol/Lysol, Harpic, Finish, Gaviscon, Durex
and Vanish.

* RBP - volume (mg) market share of Film grown to 60% up from 48% at the end
of 2011.

Consumer brand giant Reckitt Benckiser Group is reaching new high ground, after its shares finished Friday on a new 52-week high of 3,783p. That's 23% up on the price's low point of 3,100p set in November 2011, making 2012 a pretty nice year for shareholders.

Firms making consumer staples, like Reckitt Benckiser and Unilever are often considered good "safety" shares during hard times as they tend to be fairly reliable payers of dividends. Reckitt Benckiser kept its dividend growing during the downturn, and Unilever had only one down year in 2009. The share prices of both are doing well this year.

I'm not sure where they get their figures from, but the 52 week high is 3,858p!

Reckitt Benckiser to acquire Schiff Nutrition

StockMarketWire.com

Reckitt Benckiser Group has signed a definitive merger agreement with Schiff Nutrition International, Inc a leading provider of branded vitamins, nutrition supplements and nutrition bars in the US and elsewhere.

The Board of Directors of Schiff has approved the transaction and will recommend that its stockholders tender their shares into Reckitt Benckiser's previously announced cash tender offer of $42.00 per share, valuing Schiff at $1.4 billion.

Reckitt Benckiser's tender offer will expire at 11:59p.m. New York City time, on December 14, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.

Reckitt Benckiser will finance the transaction with cash and existing credit facilities. The transaction is expected to be immediately accretive to earnings on an adjusted basis.

New high today.

And again today @4080.

And again @4121.


Massachusetts Financial Services Company > 5%

4200 earlier.

New highs today @4356.

12 February 2013

Reckitt Benckiser ANNOUNCES LATAM OTC COLLABORATION

WITH BRISTOL-MYERS SQUIBB

Slough, England - 12 February, 2013 - Reckitt Benckiser Group PLC ("RB") (LSE:
RBL) today announced that it has signed a three year collaboration agreement
with Bristol-Myers Squibb ("BMS") for a number of market-leading
over-the-counter ("OTC") consumer health care brands in Brazil, Mexico and
certain other parts of Latin America (collectively "BMS Assets"), with an
option to purchase at the end of the three year period. The key brands included
under the agreement are:

Brazil Mexico

Naldecon - leading cough & cold brand Tempra - No.1 in adult and pediatric
pain relief

Luftal - No.1 in anti-flatulence Picot - No.1 in antacids

Dermodex - leading nappy rash brand Graneodin-B - No.1 in sore throat


Under this collaboration, RB will licence the brands from BMS, who will
continue to manufacture them for three years.

Rakesh Kapoor, Reckitt Benckiser Chief Executive Officer, said,

"This transaction creates a material consumer health care platform,
infrastructure and distribution network for RB in both Brazil and Mexico. As
such it is an important step in building our consumer health care presence in
Latin American emerging markets.

"These market-leading brands have strong margins and I firmly believe they have
extremely good growth potential. They fit into our existing OTC categories of
pain relief, sore throat, cough and cold, anti-acid, and dermatological and
will benefit from RB's consumer marketing and Innovation capabilities, and our
significant levels of brand equity investment."

Under the terms of the agreement RB will initially pay BMS $482 million to
enter into the arrangement which also includes personnel, supply contracts and
an option to acquire legal title to the related intellectual property at the
end of the collaboration period, based on business performance. The transaction
will be accounted for as a business combination and the Directors are in the
process of revaluing the assets and liabilities acquired to fair value,
including the value of any acquired intangible assets. Under the terms of a
separate supply agreement BMS will be RB's supplier of the products during the
collaboration period.

BMS Assets had unaudited reported net revenue for the year ended 31 December
2012 of $102 million.

We expect the transaction to be EPS* accretive from 2014 under IFRS. Excluding
the amortization we expect it to be immediately EPS* accretive(1).

The collaboration will come into effect following regulatory approvals,
including anti-trust approvals in the relevant jurisdictions. This is expected
to be completed in Q2 2013.

*Adjusted results exclude the impact of exceptional items

(1) Under IFRS a fair value of the collaboration agreement is required to be
calculated and amortized over the collaboration period.

ENDS

FY Results 2012

Highlights: Full Year

- LFL +5% ex RBP (+5% incl. RBP), well ahead of our market growth, driven by
Emerging Market Areas and Europe North America (ENA).

- Health & Hygiene led growth; Durex, Gaviscon, Strepsils, Dettol, Lysol,
Harpic and Finish.

- Increased brand equity investment (BEI) of £100m1, +70bps, (ex RBP).

- Gross margin +50bps to 57.9%. "Project Fuel" targets fully achieved.

- Adjusted operating margin** +70bps to 26.9% via gross margin expansion and
early ENA cost savings.

- Adjusted net income** +7% (+10% constant): adjusted diluted EPS of 264.4p
(+7%).

- Net working capital of minus £700m (2011: minus £701m).

- Net debt after dividends, acquisitions and restructuring of £2,426m (2011:
£1,795m).

- The Board recommends an +11% increase in the final dividend to 78p per share
bringing the total dividend for 2012 to 134p (+7% versus 2011).

Highlights: Q4

- Q4 LFL growth +6% ex RBP (+7% incl. RBP), reflecting steadily improving
in-year performance.

- Further improvement in ENA +3% LFL, assisted by higher incidences
of cold and flu.

Dividends. The Board of Directors recommends a final dividend of 78
pence (2011: 70 pence), an increase of +11%, to give a full year dividend of
134 pence (2011: 125 pence), an overall increase of +7%. The dividend, if
approved by shareholders at the AGM on 2 May 2013, will be paid on 30 May to
shareholders on the register at the record date of 22 February. The
ex-dividend date is 20 February and the last date for election for the share
alternative to the dividend is 8 May. The final dividend will be accrued once
approved by shareholders.

Prime Markets - RB. is a buy with target price £47

Up another quid today.

£45 quid this morning.

These are making new highs almost daily of late.

no wonder HG+HC index continues to spiral

Just £46.26 so far today!

here's the answer to today's slump .....

Consumer products group Reckitt Benckiser was the worst performer, slumping 182.5p at 4,333.5p on news the US FDA has given the go-ahead to rival drug manufacturers to produce a generic version of the company's Suboxone product in the US. In response, Investec downgraded its recommendation on the stock to sell from hold

==============

i would guess the drop is overdone as is the nature of these things, though when wall street opens today, there may be further selling ...... worth keeping an eye on HG+HC index, as a buying opportunity may be on the near horizon after this sharp correction - but be very aware that its volatility is scary